| Overview Malaria continues to have a devastating impact  on global human health, and greater than 40% of the world’s population is at  risk.  Annually, there are an estimated  216 million cases and 655,000 deaths due to malaria, predominantly in developing  countries.  Disease is caused by any of  five protozoan parasites.  Plasmodium falciparum and Plasmodium vivax account for the  majority of malaria cases.  No vaccines  are currently approved to prevent malaria, and treatment relies predominantly  on the use of antimalarial drugs.   However, resistance to the very limited set of efficacious drugs is  rising rapidly.  Therefore, identifying  new therapeutic targets is a high priority.  Our goal is to  establish, through technological innovations, new avenues to discovering  fundamental parasite biology that can be translated into much-needed  diagnostic, preventative and therapeutic solutions.  Ongoing research projects in the lab address: 
Tool development  for regulating gene expression; Heme metabolism in  malarial parasites; and Host-pathogen  interactions in Plasmodium falciparum. |